

Attorney Docket No.: **UIC0005US.NP**
Inventors: **Kumar et al.**
Serial No.: **Not yet assigned**
Filing Date: **Herewith**
Page 3

In the Specification:

Please add the following new paragraph after the title:

--This application is the National Stage of International Application No. PCT/US2004/025984 filed August 10, 2004, which claims the benefit of priority to U.S. Provisional Application Serial No. 60/495,161 filed August 13, 2003, U.S. Provisional Application Serial No. 60/517,809 filed November 6, 2003, and U.S. Provisional Application Serial No. 60/561,542 filed April 9, 2004, each of which are herein incorporated by reference in their entirety. This invention was made with government support under Grant number EY013605 awarded by NIH. The government has certain rights in the invention.--

Please replace the paragraph beginning at page 5, line 8, with the following rewritten paragraph:

--Particularly preferred siRNA molecules include 21-23 bases. Four specific sequences for the TGF β RII siRNA were derived from the human TGF β RII sequence (Genbank Accession Number: M85079; SEQ ID NO:159) and were designated as NK1, NK2, SS1 and SS2. The target sequences (5' to 3') are set out as below, with the position of the first nucleotide in the human TGF β RII receptor sequence (from M85079) shown in parenthesis. The corresponding commercially synthesized siRNA duplexes are also set out below:--